NOVARTIS

November 15, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2013-001562-42/ Novartis Protocol ID CSPP100A2370

A randomized, double-blind, parallel group, active-controlled study to compare the systolic blood pressure lowering efficacy of aliskiren, ramipril and a combination of aliskiren and amlodipine, with an initial 8-week evaluation, followed by a 2-3 year follow-up to compare long-term safety of an aliskiren-based regimen to a ramipril-based regimen in hypertensive patients ≥ 65 years of age.

Trial CSPP100A2370 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system only was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.